Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK+ Non-Small-Cell Lung Carcinoma”

290 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 290 results

Testing effectiveness (Phase 2)UnknownNCT03389815
What this trial is testing

A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients

Who this might be right for
Advanced Solid Tumor, Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd. 48
Large-scale testing (Phase 3)Not Yet RecruitingNCT07361484
What this trial is testing

Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)

Who this might be right for
Non-Small Cell Lung CancerNon-squamous Non-Small Cell Lung Cance
BeyondSpring Pharmaceuticals Inc. 442
Testing effectiveness (Phase 2)Active Not RecruitingNCT04127110
What this trial is testing

Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients

Who this might be right for
Non Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC 68
Not applicableStudy completedNCT01597258
What this trial is testing

Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)

Who this might be right for
Non-small Cell Lung Cancer
Pfizer 2,029
Testing effectiveness (Phase 2)Study completedNCT04997382
What this trial is testing

Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital 112
Not applicableWithdrawnNCT05116618
What this trial is testing

Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged

Who this might be right for
Non-Small Cell Lung Cancer
University of Colorado, Denver
Large-scale testing (Phase 3)Active Not RecruitingNCT06569420
What this trial is testing

Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC

Who this might be right for
Non-Small Cell Lung CancerALK-positiveSAF-189s
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 275
Testing effectiveness (Phase 2)Study completedNCT03535740
What this trial is testing

Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

Who this might be right for
ALK-positive Advanced NSCLC
Ariad Pharmaceuticals 103
Testing effectiveness (Phase 2)WithdrawnNCT06522360
What this trial is testing

Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)

Who this might be right for
Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Early research (Phase 1)Ended earlyNCT04005144
What this trial is testing

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

Who this might be right for
ALK Gene RearrangementLung Non-Small Cell CarcinomaProgressive Disease+6 more
University of California, San Francisco 3
Large-scale testing (Phase 3)Looking for participantsNCT06765109
What this trial is testing

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Who this might be right for
Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positive
Nuvalent Inc. 450
Testing effectiveness (Phase 2)Active Not RecruitingNCT05020457
What this trial is testing

SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

Who this might be right for
Non Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 69
Testing effectiveness (Phase 2)Ended earlyNCT02584634
What this trial is testing

Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

Who this might be right for
Non-Small Cell Lung Cancer
Pfizer 43
Post-approval studies (Phase 4)Not Yet RecruitingNCT06893354
What this trial is testing

Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

Who this might be right for
NSCLC
The First Affiliated Hospital of Guangzhou Medical University 20
Testing effectiveness (Phase 2)Study completedNCT04677595
What this trial is testing

Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals 36
Testing effectiveness (Phase 2)Ended earlyNCT03737994
What this trial is testing

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Who this might be right for
Lung Non-Squamous Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8+1 more
National Cancer Institute (NCI) 10
Testing effectiveness (Phase 2)UnknownNCT03215693
What this trial is testing

X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Who this might be right for
Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 152
Testing effectiveness (Phase 2)UnknownNCT05801107
What this trial is testing

Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd. 30
Not applicableStudy completedNCT02010047
What this trial is testing

Comparison of qPCR to IHC and FISH for Detection of ALK Fusion Mutations in FFPE Tissue From NSCLC Patients

Who this might be right for
Nonsmall Cell Lung Cancer
British Columbia Cancer Agency 166
Testing effectiveness (Phase 2)UnknownNCT04989322
What this trial is testing

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Who this might be right for
NsclcEGFR Activating MutationEGF-R Positive Non-Small Cell Lung Cancer+3 more
Dr Joanne CHIU 46
Next Page